These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 33745865

  • 1. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
    Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR.
    Clin Lung Cancer; 2021 Jul; 22(4):313-323.e1. PubMed ID: 33745865
    [Abstract] [Full Text] [Related]

  • 2. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Mizugaki H, Yamamoto N, Nokihara H, Fujiwara Y, Horinouchi H, Kanda S, Kitazono S, Yagishita S, Xiong H, Qian J, Hashiba H, Shepherd SP, Giranda V, Tamura T.
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
    [Abstract] [Full Text] [Related]

  • 3. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.
    Kozono DE, Stinchcombe TE, Salama JK, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Chen X, Sun Z, Nuthalapati S, Rosenwinkel L, Johnson EF, Bach BA, Luo Y, Vokes EE.
    Lung Cancer; 2021 Sep; 159():56-65. PubMed ID: 34311345
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.
    Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, Urban L, Orlov S, Barlesi F, Kio E, Keiholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Ansell P, McKee M, Giranda V, Gorbunova V.
    Clin Cancer Res; 2017 Apr 15; 23(8):1937-1944. PubMed ID: 27803064
    [Abstract] [Full Text] [Related]

  • 6. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE.
    Lancet Oncol; 2018 Apr 15; 19(4):497-509. PubMed ID: 29501363
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T.
    Invest New Drugs; 2022 Feb 15; 40(1):106-114. PubMed ID: 34495421
    [Abstract] [Full Text] [Related]

  • 9. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H.
    Lancet Oncol; 2015 Feb 15; 16(2):187-99. PubMed ID: 25601342
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM.
    J Thorac Oncol; 2008 Jan 15; 3(1):59-67. PubMed ID: 18166842
    [Abstract] [Full Text] [Related]

  • 11. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
    Tanaka H, Hasegawa Y, Makiguchi T, Okumura F, Tabe C, Shiratori T, Ishioka Y, Itoga M, Taima K, Yokouchi J, Hatayama Y, Aoki M, Tasaka S.
    Clin Lung Cancer; 2021 Jan 15; 22(1):42-48. PubMed ID: 33158764
    [Abstract] [Full Text] [Related]

  • 12. nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.
    Lammers PE, Lu B, Horn L, Shyr Y, Keedy V.
    Oncologist; 2015 May 15; 20(5):491-2. PubMed ID: 25845992
    [Abstract] [Full Text] [Related]

  • 13. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
    Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J.
    J Clin Oncol; 2001 Jan 15; 19(2):442-7. PubMed ID: 11208837
    [Abstract] [Full Text] [Related]

  • 14. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
    Ross HJ, Kozono D, Wang XF, Urbanic JJ, Williams TM, Nelson GD, Carbone DP, Chung D, Robb R, Byun WY, Talabere T, DuFrane C, Bara I, Schulze K, Brockman M, Gao J, Vokes EE, Stinchcombe TE.
    JAMA Oncol; 2024 Sep 01; 10(9):1212-1219. PubMed ID: 39052256
    [Abstract] [Full Text] [Related]

  • 15. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH.
    Clin Lung Cancer; 2020 Nov 01; 21(6):520-526. PubMed ID: 32807654
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR, SWOG S9712.
    J Clin Oncol; 2006 Nov 20; 24(33):5242-6. PubMed ID: 17114656
    [Abstract] [Full Text] [Related]

  • 17. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer.
    Guilbault C, Garant A, Faria S, Owen S, Ofiara L, Duclos M, Hirsh V, Kopek N.
    Clin Lung Cancer; 2017 Sep 20; 18(5):565-571. PubMed ID: 28344046
    [Abstract] [Full Text] [Related]

  • 18. Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
    Niho S, Hosomi Y, Okamoto H, Nihei K, Tanaka H, Hida T, Umemura S, Goto K, Akimoto T, Ohe Y.
    Jpn J Clin Oncol; 2019 Jul 01; 49(7):614-619. PubMed ID: 30916304
    [Abstract] [Full Text] [Related]

  • 19. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
    Wang J, Pang QS, Wang P, Wang J, Wang W.
    Zhonghua Zhong Liu Za Zhi; 2007 Oct 01; 29(10):769-72. PubMed ID: 18396691
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.